title: Long-term survival in acute leukemia in Argentina: a study of 78 cases.
abstract: A total of 78 patients with acute leukemia [69 acute lymphoblastic leukemia (ALL) and 9 acute myeloblastic leukemia (AML)] survived more than 4 years. In the years between 1958 and 1967 the number of patients with ALL in Argentina who survived 4 years was 1%. This increased to 21% in the years between 1967 and 1972. The major cause of this increase was the initiation in 1967 of protocols of therapy on a national scale through a cooperative group known as GATLA. In AML patients the number of long-term survivals remained unchanged during both periods. A large percent of the long-term survivors had lower WBC, a higher platelet count, and no hepato- or splenomegaly, lymphadenopathy, or hemorrhagic manifestations at diagnosis. However, only for those patients with a WBC under 100,000/mm3 at diagnosis was there a significant prognostic implication (p less than 0.01). Patients with acute lymphoblastic leukemia who survive more than 4 years without relapse have about an 80% chance of long survival. For those who have lived 4 years with one or more lapses, there is only a 17% chance of long survival, and of these only those who develop extramedullar relapse (CNS or testicular) without bone marrow involvement have a chance of long survival. Patients who live 4 years in continuous complete remission have the same chance of very long survival regardless of previous therapy.
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001118:Argentina; D001772:Blood Cell Count; D002493:Central Nervous System Diseases / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000401:mortality*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013736:Testicular Neoplasms / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents